Evidence map›Paper›PMID 36771041›Full record

ArticleMolecules (Basel, Switzerland)2023

Identifying the Anti-MERS-CoV and Anti-HcoV-229E Potential Drugs from the

Ezzat H Elshazly, Alyaa Nasr, Mohamed E Elnosary, Gamal A Gouda, Hassan Mohamed, Yuanda Song

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Bioactive Compounds fromCurrent pharmaceutical biotechnology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Exploring biosurfactant fromFrontiers in bioengineering and biotechnology · 2024
    Article
  8. Frontiers in bioengineering and biotechnology · 2024
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ezzat H ElshazlyDepartment of Botany and Microbiology, Faculty of Science, Al-Azhar University, Assiut 71524, Egypt.
Alyaa NasrDepartment of Botany and Microbiology, Faculty of Science, Menoufia University, Shebin El-Kom 32511, Egypt.ORCID 0000-0003-2222-2301
Mohamed E ElnosaryDepartment of Botany and Microbiology, Faculty of Science, Al-Azhar University, Nasr City 11884, Egypt.ORCID 0000-0002-7152-8625
Gamal A GoudaDepartment of Chemistry, Faculty of Science, Al-Azhar University, Assiut 71524, Egypt.ORCID 0000-0001-6419-5458
Hassan MohamedDepartment of Botany and Microbiology, Faculty of Science, Al-Azhar University, Assiut 71524, Egypt.ORCID 0000-0002-5687-2305
Yuanda SongColin Ratledge Center for Microbial Lipids, School of Agricultural Engineering and Food Science, Shandong University of Technology, Zibo 255000, China.ORCID 0000-0002-8565-6724

Funding

National Natural Science Foundation of China 31972851 and 31670064TaiShan Industrial Experts Programme 20160101
6 · The paper itself

Abstract

The present study aimed to estimate the antiviral activities of

Indexed as

Coronavirus 229E, HumanCoronavirus InfectionsMetal NanoparticlesMiddle East Respiratory Syndrome CoronavirusAnti-Bacterial AgentsGinkgo bilobaHumansPlant ExtractsSilverSpectroscopy, Fourier Transform InfraredX-Ray DiffractionAnti-Bacterial AgentsPlant ExtractsSilveranti-coronavirusGinkgo bilobanatural productssilver nanoparticles

Identifiers

PMID36771041
PMCPMC9919260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.